Evidence map›Paper›PMID 38411628›Full record

ArticleAnnals of hematology2024

Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.

Keiichiro Fujii, Atsushi Inagaki, Ayako Masaki, Mariko Sugiura, Tomotaka Suzuki, Takashi Ishida, Shigeru Kusumoto, Shinsuke Iida, Hiroshi Inagaki

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Keiichiro FujiiDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan.
Atsushi InagakiDepartment of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Ayako MasakiDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan.
Mariko SugiuraDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan.
Tomotaka SuzukiDepartment of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Takashi IshidaDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shigeru KusumotoDepartment of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Shinsuke IidaDepartment of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Hiroshi InagakiDepartment of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan. hinagaki@med.nagoya-cu.ac.jp.ORCID http://orcid.org/0000-0001-6157-636X
Nagoya City University · JPNagoya University · JP

Funding

Japan Society for the Promotion of Science 21K15405
6 · The paper itself

Abstract

The international prognostic index (IPI) system has been widely used to predict prognosis in diffuse large B-cell lymphoma (DLBCL). However, this system categorizes DLBCL patients into four risk groups, and cannot optimize individualized prognosis. In addition, other clinicopathological factors, such as molecular aberrations, are not incorporated into the system. To partly overcome these weak points, we developed nomograms to predict individual patient survival. We also incorporated MYD88

Indexed as

CD79 AntigensLymphoma, Large B-Cell, DiffuseMutationMyeloid Differentiation Factor 88NomogramsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedPrognosisSurvival RateCD79 AntigensCD79B protein, humanMYD88 protein, humanMyeloid Differentiation Factor 88CD79BDLBCLMYD88NomogramPrognosis

Identifiers

PMID38411628
OpenAlexW4392193816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.